Laurus Labs Ltd (LAURUSLABS) — shareholding pattern, promoter holding, financials and share price

About Laurus Labs Ltd (LAURUSLABS)

Laurus Labs Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as LAURUSLABS and on the BSE under scrip code 540222. Its ISIN is INE947Q01028.

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]

Laurus Labs is a leading pharmaceutical and biotechnology company specializing in generic APIs and FDFs, with a strong focus on ARVs, oncology, and hepatitis treatments.

The company achieved a remarkable 30% revenue growth, reaching ₹5,001 crore, driven by strong performance in its CDMO and Generics divisions, demonstrating robust operational efficiency.

Listed peers in Pharmaceuticals: Mankind Pharma Ltd, Dr Reddys Laboratories Ltd, Aurobindo Pharma Ltd, Biocon Ltd, Alkem Laboratories Ltd, Glenmark Pharmaceuticals Ltd.

Valuation & Returns

10 Jul 2026

At ₹1,534 a share on 10 Jul 2026, Laurus Labs Ltd (LAURUSLABS) was valued at a price-to-earnings ratio of 93.13x against an industry P/E of 36.41x and a price-to-book of 15.64x on a book value of ₹98.1 per share as of Mar 2026. Solomo computes return on equity of 16.79% and return on capital employed of 17.3% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.

P/E
93.13x
Industry P/E
36.41x
P/B
15.64x
EPS (TTM)
₹16.47
Book value / share
₹98.1
ROE
16.79%
ROCE
17.3%
ROA
8.47%
Debt / equity
0.48x
Dividend yield
0.13%
EBITDA margin
26.9%
52-week range
₹787.1 – ₹1,555

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2026

In the year ended Mar 2026, Laurus Labs Ltd (LAURUSLABS) reported revenue of ₹6,813 crore, net profit of ₹890 crore and earnings per share of ₹16.46. That compares with revenue of ₹5,554 crore and net profit of ₹358 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹1,812 crore and net profit ₹282 crore (consolidated).

Consolidated annual results for Laurus Labs Ltd (LAURUSLABS), Mar 2022 to Mar 2026. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue (₹ cr)4,9366,0415,0415,5546,813
Net profit (₹ cr)832793162358890
EPS (₹)15.414.672.986.6416.46
Compound annual growth for Laurus Labs Ltd (LAURUSLABS). Stock price CAGR is price return and excludes dividends.
Measure10Y5Y3Y1Y
Sales growth13.69%5.01%1.79%22.67%
Profit growth15.66%-4.98%-0.88%151.08%
Stock price CAGR-18%64%89%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 27.47% of Laurus Labs Ltd (LAURUSLABS) (down 0.02 pp QoQ), foreign institutional investors (FII) hold 28% and domestic institutional investors (DII) hold 13.74%. Promoters have pledged 2.7% of their holding. Market capitalisation was ₹82,874 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2016.

Largest disclosed public shareholders in Jun 2026: MIRAE ASSET LARGE & MIDCAP FUND 4.33%, NEW WORLD FUND INC 4.28%, ANUKAR PROJECTS PRIVATE LIMITED 3.24%, SMALLCAP WORLD FUND, INC 2.77%, BARCLAYS WEALTH TRUSTEES INDIA PRIVATE LIMITED 1.55%, AKASH BHANSHALI 1.32%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202627.47%2.7%28%13.74%72.53%
Mar 202627.49%2.7%25.82%13.97%72.51%
Dec 202527.49%2.7%26.52%12.43%72.51%
Sep 202527.59%2.7%26.16%11.73%72.41%
Jun 202527.59%2.7%25.7%11.94%72.41%
Mar 202527.62%2.7%25.52%11.77%72.38%
Dec 202427.62%2.7%25.56%12.74%72.38%
Sep 202427.18%-26.08%13.05%72.82%
Every quarter since Dec 2016 Promoter pledge history Filing data, not investment advice.